|
|
Volumn 292, Issue 4, 2004, Pages
|
|
"Promiscuous" anticancer drugs that hit multiple targets may thwart resistance
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
CYTOKINE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
IMATINIB;
PLATELET DERIVED GROWTH FACTOR;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
RAF PROTEIN;
SORAFENIB;
STEM CELL FACTOR RECEPTOR;
SUNITINIB;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
VASCULOTROPIN RECEPTOR;
CELL SURFACE RECEPTOR;
NEW DRUG;
ANTINEOPLASTIC ACTIVITY;
CANCER;
CANCER INHIBITION;
CANCER RESISTANCE;
DRUG BINDING;
DRUG EFFICACY;
DRUG RESEARCH;
DRUG TARGETING;
HUMAN;
PRIORITY JOURNAL;
REVIEW;
ARTICLE;
DRUG DELIVERY SYSTEM;
DRUG EFFECT;
ANTINEOPLASTIC AGENTS;
DRUG DELIVERY SYSTEMS;
DRUGS, INVESTIGATIONAL;
HUMANS;
RECEPTORS, CELL SURFACE;
|
|
EID: 3242802116
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.292.4.419 Document Type: Review |
|
Times cited : (48)
|
|
References (0)
|